Von Willebrand Disease Drugs Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | and Therapeutics, TagCyx Biotechnologies, China Biologic Products, Thrombotargets Corporation, Sanofi

DelveInsight's "Von Willebrand Disease Market Insights, Epidemiology, and Market Forecast- 2034" report delivers an in-depth understanding of the Von Willebrand Disease, historical and forecasted epidemiology as well as the Von Willebrand Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover which therapies are expected to grab the Von Willebrand Disease Market Share @ Von Willebrand Disease Market Outlook- https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Von Willebrand Disease Market Report
• In April 2025, Baxalta conducted a study is to check effectiveness, side effects, and tolerability of vonicog alfa (recombinant von Willebrand factor [rVWF]), with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric participants (less than (45 years reported around 6%, 23%, and 17% cases, respectively, in 2023.
• Von Willebrand disease Type 2 and Type 3 accounts for around 11% and 6% of all Von Willebrand Disease diagnosed prevalent cases in the US, in 2023. Whereas, von willebrand disease Type 1 reported around 83% cases alone, in 2023.
• The increase in Von Willebrand Disease Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Von Willebrand Disease Market is anticipated to witness growth at a considerable CAGR.
• The leading Von Willebrand Disease Companies such as Band Therapeutics, TagCyx Biotechnologies, China Biologic Products, Thrombotargets Corporation, Sanofi and others.
• Promising Von Willebrand Disease Pipeline Therapies such as VGA039, Wilate, Oprelvekin, Vonicog Alfa, rVWF, rFVIII and others.

Stay ahead in the Von Willebrand Disease Therapeutics Market with DelveInsight's Strategic Report @ Von Willebrand Disease Market Outlook- https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Von Willebrand Disease Epidemiology Segmentation in the 7MM
The epidemiology section of Von Willebrand Disease offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
• Total Diagnosed Prevalent Population Cases
• Gender-Specific Diagnosed Prevalent Population Cases
• Type-Specific Diagnosed Prevalent Population Cases
• Age-Specific Diagnosed Prevalent Population Cases

Download the report to understand which factors are driving Von Willebrand Disease Epidemiology trends @ Von Willebrand Disease Prevalence- https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Von Willebrand Disease Marketed Drugs
• WILATE: OctaPharma
WILATE is the first von Willebrand factor (VWF) concentrate indicated for prophylactic treatment across all forms of Von Willebrand disease, marking a significant milestone in the field. In December 2023, Octapharma USA announced the expansion of the US FDA approval for WILATE, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection. The approved label now includes routine prophylaxis aimed at reducing the frequency of bleeding episodes in adults and children aged 6 and older with any type of von Willebrand disease, the most prevalent bleeding disorder in the United States. The FDA approval is supported by Octapharma's WIL-31 study, a prospective, non-controlled, international, multicenter Phase III trial that investigated the efficacy and safety of wilate prophylaxis over 12 months in people aged 6 and older with severe Von Willebrand disease of any type.

• VONVENDI: Takeda Pharmaceuticals
VONVENDI is a recombinant von Willebrand factor replacement therapy. It is approved for the treatment to reduce the frequency of bleeding episodes for severe type 3 von Willebrand disease. In January 2022, US FDA approved VONVENDI [von Willebrand Factor (Recombinant)] for routine prophylaxis treatment in patients with severe Type 3 von Willebrand disease receiving on-demand therapy. The approval was based on data from a prospective, open-label, international multicenter study that evaluated efficacy and safety of prophylactic treatment. Investigators observed whether frequency of bleeding episodes were reduced in 10 adult patients diagnosed with severe Type 3 von Willebrand disease, who were previously treated on-demand.

Von Willebrand Disease Emerging Drugs
• VGA039: Vega Therapeutics
Vega Therapeutics' VGA039 is a first-in-class antibody therapy with a novel mechanism of action that modulates Protein S - a key co-factor involved in thrombin generation during both initiation and propagation of coagulation - with preclinical data demonstrating efficacy in numerous congenital bleeding disorders, including von Willebrand disease. By promoting thrombin generation through targeting Protein S, VGA039 addresses a fundamental mechanism of clot formation in Von Willebrand disease and, as a subcutaneously self-administered antibody therapy, has potential to transform von Willebrand disease treatment. It is currently recruiting in a Phase I study to assess safety, tolerability, pharmacokinetic, and pharmacodynamics study of VGA039 following IV or SC administration of single ascending doses in healthy adults and subcutaneous adult patients with von willebrand disease. In May 2023, the US FDA granted VGA039 Orphan Drug Designation.

• Efanesoctocog alfa (BIVV001): Sanofi
Efanesoctocog alfa (BIVV001), is a novel and investigational recombinant factor VIII therapy. It builds on the innovative Fc fusion technology by adding a region of von Willebrand factor and XTEN polypeptides to extend its time in circulation. It is the first investigational factor VIII therapy that has been shown to break through the von Willebrand factor ceiling, which imposes a half-life limitation on current factor VIII therapies. It is being developed by Sanofi to assess the pharmacokinetics and safety and tolerability of efanesoctocog alfa (BIVV001) in adults with Type 2N and 3 Von Willebrand disease. It is currently under Phase I development.

Von Willebrand Disease Drugs Market
The Von Willebrand Disease Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Von Willebrand Disease signaling in Von Willebrand Disease are likely to uncover new therapeutic targets and further expand treatment options for patients.

To learn more about Von Willebrand Disease treatment guidelines, visit @ Von Willebrand Disease Treatment Market Landscape- https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Major Von Willebrand Disease Companies
Band Therapeutics, TagCyx Biotechnologies, China Biologic Products, Thrombotargets Corporation, Sanofi and others.

Von Willebrand Disease Market Outlook
The current Von Willebrand Disease therapeutics market landscape in the United States can be divided into three major categories based on the class of drugs administered, they are; Non-replacement Therapy using desmopressin (DDAVP) to increase the plasma concentration of vWF, Replacement Therapy using plasma-derived coagulation factor concentrates (HUMATE-P, ALPHANATE, IMMUNATE, and WILATE) and Adjunct Therapy using primarily anti-fibrinolytics, such as Tranexamic Acid (CYCLOKAPRON).

Von Willebrand Disease Treatment Market Landscape
The Von Willebrand Disease treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Von Willebrand Disease has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

Learn more about the FDA-approved drugs for Von Willebrand Disease @ Drugs for Von Willebrand Disease Treatment- https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Von Willebrand Disease Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Von Willebrand Disease Companies- Band Therapeutics, TagCyx Biotechnologies, China Biologic Products, Thrombotargets Corporation, Sanofi and others.
• Von Willebrand Disease Pipeline Therapies- VGA039, Wilate, Oprelvekin, Vonicog Alfa, rVWF, rFVIII and others.
• Von Willebrand Disease Market Dynamics: Von Willebrand Disease Market Drivers and Barriers
• Von Willebrand Disease Market Access and Reimbursement, Unmet Needs and Future Perspectives, Von Willebrand Disease Clinical Trials

Discover more about Von Willebrand Disease Drugs in development @ Von Willebrand Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Key Insights
2. Von Willebrand Disease Executive Summary
3. Von Willebrand Disease Competitive Intelligence Analysis
4. Von Willebrand Disease: Market Overview at a Glance
5. Von Willebrand Disease: Disease Background and Overview
6. Patient Journey
7. Von Willebrand Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Von Willebrand Disease Unmet Needs
10. Key Endpoints of Von Willebrand Disease Treatment
11. Von Willebrand Disease Marketed Products
12. Von Willebrand Disease Emerging Therapies
13. Von Willebrand Disease: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Von Willebrand Disease Market Outlook
16. Access and Reimbursement Overview of Von Willebrand Disease
17. KOL Views
18. Von Willebrand Disease Market Drivers
19. Von Willebrand Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2025

Pulmonary emphysema market- https://www.delveinsight.com/report-store/pulmonary-emphysema-market
Urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
Vital sign monitors devices market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cardiac implantable electronic devices market- https://www.delveinsight.com/report-store/cardiac-implantable-electronic-devices-cieds-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-pipeline-insight
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
HIP Replacement devices market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Indwelling catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
LY3454738 drug insight- https://www.delveinsight.com/report-store/moderate-to-severe-atopic-dermatitis-pipeline-insight
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
Sepsis market_ https://www.delveinsight.com/report-store/sepsis-market-insight
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Coronary stents market- https://www.delveinsight.com/report-store/stents-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/
India:- +91-9650213330

This release was published on openPR.